UC WAR. PUT 06/24 OMV/ DE000HC7E148 /
13/05/2024 21:46:51 | Diferencia-0.0050 | Bid21:59:26 | Ask21:59:26 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
0.0320EUR | -13.51% | 0.0010 Volumen de oferta: 15,000 |
0.0720 Tamaño/ Volumen/ Formato de Ask: 15,000 |
OMV AG | 40.00 EUR | 19/06/2024 | Put |
GlobeNewswire
6:00
SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING ...
GlobeNewswire
5:01
MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible S...
GlobeNewswire
4:10
Kilmer Sports Ventures Enters into Exclusive Negotiations to Acquire French Professional Football Cl...
GlobeNewswire
3:50
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3:00
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024
GlobeNewswire
3:00
GLOBAL LIFE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Bee...
GlobeNewswire
2:29
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders...
GlobeNewswire
2:06
MBUU INVESTOR ALERT: Edelson Lechtzin LLP Urges Malibu Boats, Inc. (NASDAQ: MBUU) Shareholders With ...
GlobeNewswire
2:00
ROSEN, A LEADING LAW FIRM, Encourages Rivian Automotive, Inc. Investors With Losses in Excess of $10...
GlobeNewswire
2:00
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- an...
GlobeNewswire
2:00
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatme...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página